Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict ICU death risk for cancer patients

NCT ID NCT07656311

Knowledge-focused Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed in the ICU for more than 24 hours between 2020 and 2025. No new tests or treatments are given—the goal is simply to see if MPV levels are linked to survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a simple, early way to identify which cancer patients in the ICU are at highest risk, helping them make faster treatment decisions.
What could go wrong
This is an observational study that only looks back at past records. It cannot prove cause and effect, and the results may not apply to all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

425 people

The number who actually took part.

Started

Jun 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult oncological patients who required critical care and were admitted to the anesthesia intensive care unit of a tertiary oncology training and research hospital between 2020 and 2025.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years and older. * Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies). * Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025. * Patients with an ICU length of stay longer than 24 hours. * Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission. Exclusion Criteria: * Patients under the age of 18. * Patients who stayed in the intensive care unit for less than 24 hours. * Patients with missing or incomplete medical charts, laboratory data, or survival status records. * Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated). * Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Critical Illness neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Critical illness Mortality

Contacts and locations

Locations

  • Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital

    Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.